By: Azia Tariq, Staff Editor – Truly personalized medication is the goal of researchers in the pharmaceutical and biotechnological industries. For example, when a patient requires a precise dose that is not manufactured as a tablet, the tablet will be broken up in order to deliver the dose as close as possible. Not only is…

By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.…

By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] and Jenny Prakash, PharmD Candidate c/o 2014 – Starting your rotations in 5th year usually brings mixed emotions. On one hand, it’s a relief to finally be finished with labs and D&Ds…imagine, a whole year without any exams! But on the other hand, now you have to test how…

By: Sang Hyo Kim, Staff Editor – Near the end of December, the pharmaceutical company, MannKind Corp, will submit their clinical data to the U.S Food and Drug Administration for the approval of an inhaled dosage form of insulin, Afrezza®.1 Administered with the Dreamboat inhaler, this inhaled dosage form delivers insulin packaged into single dose…

By: Hayeon Na, Co-Copy Editor [Content-Focused] – The Food and Drug Administration (FDA) announced on July 26th that oral dosage forms of ketoconazole (Nizoral®) should no longer be prescribed as first-line therapy for any fungal infections.1 The label and indication for oral ketoconazole were updated, and a new medication guide was added. Other dosage forms…

By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1  This occurred one month after its approval in  Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is…

By: Eugene Kolomiyets, PharmD Candidate c/o 2013, AMSCOP at LIU – Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7.1  The disease has been linked to thousands of possible mutations, but only as many as 25-30 are tested for…

By: Neal Shah, Co-Editor-in-Chief – Xerostomia, commonly known as dry mouth, is an anti-muscarinic side effect of numerous medications.  Antidepressants, analgesics, diuretics, and antihistamines have a high propensity to cause xerostomia.1  Xerostomia may also result from Sjogren’s syndrome, Parkinson’s disease, and various chemotherapy agents.2  Traditionally, muscarinic agonists like pilocarpine have been used to reverse xerostomia.…

By: Mohamed Dungersi & Mahdieh Danesh Yazdi, Associate Student Editors – Each month, the editors at the Rho Chi Post have the opportunity to interview one or more of our faculty members. This month, we had the tremendous opportunity to interview the dean of St. John’s University College of Pharmacy and Allied Health Professions, Dean…

By: Mohamed Dungersi, Associate Student Editor – Dr. William Maidhof is an Assistant Professor and Industry Professional in the Clinical Pharmacy Practice department of the St. John’s University College of Pharmacy and Allied Health Professions. He is an alumnus of St. John’s University who graduated in 1999 with a BS in Pharmacy and again in…

By: Alexandra Alleva, Pharm.D. Candidate c/o 2013 – On February 17, 2012, the US Food and Drug Administration (FDA) approved the first medication indicated specifically for patients with endogenous Cushing’s syndrome, a hormone disorder characterized by elevated blood levels of cortisol.  Mifepristone (Korlym®) is for the treatment of glucose intolerance and Type 2 Diabetes Mellitus…

By: Ebey P. Soman – The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto®) for the treatment of type 2 diabetes.  Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes. Prescribers may add a…

By: Aleena Chacko, Long Island University Pharm.D. Candidate c/o 2013 – Established in 1996, Novartis International AG is a multinational pharmaceutical company based in Switzerland.  On January 8, 2012, Novartis issued a recall on some popular over the counter (OTC) medications in the United States (U.S.) over concerns about broken or incorrect tablets ending up…